IMNN (Imunon Inc) רווח נקי למניה ב-12 החודשים האחרונים

The 12-month net income per share trend for Imunon, Inc. (IMNN) highlights the implementation of laboratory automation for molecule analysis. The business relies on the development of DNA vaccines against ovarian cancer and the licensing of Theraiva. Demand for oncology research remains stable, ensuring resilience to macroeconomic shocks, while the value of -3.31 serves as the current reading for this fundamental metric.

This indicator reflects the portion of net income attributable to a single common share over the past year. The calculation is based on dividing total income minus all expenses by the total number of shares outstanding. By analyzing the net income per share over 12 months, an investor assesses the real efficiency of capital generation. For Imunon, Inc. (IMNN), this trend confirms financial stability during the implementation of sustainable production standards for DNA-based drugs. Growth in net income per share over 12 months signals the successful optimization of biotechnological laboratories.